News Story: Full Text
Sponsored By
Tocagen Clinical Trial
Please Click On The Above Banner For More Details
Braintumor Website

 

Controversies in the Adjuvant Therapy of High-Grade Gliomas


Posted on: 02/21/2011

Neuro-Oncology

Controversies in the Adjuvant Therapy of High-Grade Gliomas

Matthias HoldhoffStuart A. Grossman

Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Key Words. Glioblastoma multiforme • Anaplastic astrocytoma • Anaplastic oligodendroglioma • Anaplastic oligoastrocytoma • Low-grade glioma • Adjuvant therapy • Temozolomide • Chemotherapy

Correspondence: Correspondence: Matthias Holdhoff, M.D., Ph.D., Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building II, 1550 Orleans Street, 1M16, Baltimore, Maryland 21231, USA. Telephone: 410-955-8837; Fax: 410-614-9335; e-mail: mholdho1@jhmi.edu

Received October 5, 2010; accepted for publication January 7, 2011.

Disclosures: Matthias Holdhoff: None; Stuart A. Grossman:Consultant/advisory role: Merck, Roche. 

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Abstract The 2-year survival rate of patients with glioblastoma accrued to research studies increased from 10% to nearly 40% from 2000 to 2010. These improvements began with the demonstration of a survival benefit when daily temozolomide was administered with 6 weeks of standard radiation and for 6 months thereafter. This treatment regimen is often associated with significant lymphopenia, thrombocytopenia, and progressive blood–brain barrier dysfunction that can result in clinical and radiologic deterioration without true tumor progression ("pseudoprogression"). With new evidence that combining this cytotoxic agent with radiation improves survival in this malignancy, many investigators have modified the regimen to further improve patient outcomes. Theselargely uncontrolled studies highlight controversies regarding the optimal therapy of this disease. This review focuses on the following selected controversies: (a) What is the appropriate temozolomide dose, schedule, and duration in the postradiation period? (b) How should other U.S. Food and Drug Administration–approvedtherapies (such as carmustine wafers and bevacizumab) be incorporated into this treatment regimen? (c) Should the results in glioblastoma be extrapolated to patients aged >70 and to patients with lower grade gliomas? and (d) How should novel therapeutic approaches be added to radiation and temozolomide in clinical trials for patients with newly diagnosed glioblastoma?

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740